Neurocrine Biosciences (NBIX) Non-Current Deffered Revenue (2010 - 2018)
Neurocrine Biosciences (NBIX) posted quarterly Non-Current Deffered Revenue of $18.1 million for Q4 2018, up 77.05% year-over-year from $10.2 million in Q4 2017, and up 49.62% on a QoQ basis from $12.1 million in Q3 2018.
Neurocrine Biosciences (NBIX) Non-Current Deffered Revenue (2010 - 2018) Analysis & Trends
Neurocrine Biosciences has reported Non-Current Deffered Revenue for 9 years, with the latest figure at $18.1 million in Q4 2018.
- Non-Current Deffered Revenue for Q4 2018 came in at $18.1 million, up 77.05% year-over-year; the trailing twelve-month figure through Dec 2018 was $18.1 million (up 77.05% YoY), and the FY2018 annual result was $18.1 million, up 77.05% from the prior year.
- Non-Current Deffered Revenue rose to $18.1 million in Q4 2018, from $12.1 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $18.1 million in Q4 2018 and troughed at $10.2 million in Q1 2016.
- A 5-year average of $12.2 million and a median of $10.6 million in 2015 frame the typical range for Non-Current Deffered Revenue.
- The widest annual swing landed in 2016, when Non-Current Deffered Revenue slipped 24.03%; it then soared 77.05% in 2018.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $14.3 million in 2014, then dropped by 23.91% to $10.9 million in 2015, then dropped by 6.12% to $10.2 million in 2016, then changed by 0.0% to $10.2 million in 2017, then soared by 77.05% to $18.1 million in 2018.
- Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $18.1 million in Q4 2018, $12.1 million in Q3 2018, and $10.2 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.31 Bn | 39.66 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.65 Bn | 29.98 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.18 Bn | 19.52 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.82 Bn | 17.94 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.70 Bn | 15.31 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 7.31 Mn |
| Sep 30, 2018 | 7.50 Mn |
| Jun 30, 2018 | 5.33 Mn |
| Mar 31, 2018 | 10.23 Mn |
| Dec 31, 2017 | 8.04 Mn |
| Sep 30, 2017 | 3.16 Mn |
| Jun 30, 2017 | 1.69 Mn |
| Mar 31, 2017 | 6.47 Mn |
| Dec 31, 2016 | 1.46 Mn |
| Sep 30, 2016 | 1.59 Mn |
| Jun 30, 2016 | 10.23 Mn |
| Mar 31, 2016 | 1.82 Mn |
| Dec 31, 2015 | 10.90 Mn |
| Sep 30, 2015 | 10.23 Mn |
| Jun 30, 2015 | 12.61 Mn |
| Mar 31, 2015 | 1.82 Mn |
| Sep 30, 2014 | 15.16 Mn |
| Jun 30, 2014 | 15.99 Mn |
| Mar 31, 2014 | 16.82 Mn |
| Dec 31, 2013 | 1.98 Mn |